MTOR and endometrial cancer: Several studies have reported that simvastatin inhibits adhesion and invasion in leukemias, hepatocellular cancer, melanoma and endometrial cancer through multiple cell signaling pathways such as the ROCK, MAPK and mTOR pathways [21, 25, 33–35].